For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Aliskiren - Hypertension
PAD Profile : Aliskiren - Hypertension Important
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Bendroflumethiazide
- Candesartan cilexetil
- Eprosartan
- Indapamide
- Irbesartan
- Losartan potassium
- Olmesartan medoxomil
- Valsartan
- Ramipril
- Amlodipine
- Lisinopril
- Bisoprolol fumarate
- Doxazosin mesilate
- Diltiazem hydrochloride
- Nifedipine
- Perindopril erbumine
- Telmisartan
- Moxonidine
- Co-tenidone (Atenolol/chlortalidone)
- Enalapril maleate
- Quinapril hydrochloride
- Nebivolol
- Perindopril arginine
- Metolazone
- Azilsartan medoxomil
- Captopril
- Lercanidipine hydrochloride
- Nicardipine hydrochloride
- Chlortalidone
- Spironolactone
- Atenolol
- Carvedilol
- Celiprolol hydrochloride
- Metoprolol tartrate
- Propranolol hydrochloride
- Prazosin hydrochloride
- Clonidine hydrochloride
- Hydralazine hydrochloride
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
The Area Prescribing Committee does not recommend the use of aliskiren in line with NHS England guidance.
Aliskiren will be considered BLACK on the traffic light system. Prescribers should:
- NOT initiate aliskiren for any new patient
AND
- Change patients taking aliskiren to an alternative antihypertensive in line with NICE on the diagnosis and management of hypertension in adults noting that it is important that blood pressure is monitored closely and to consider treatments that may not have previously been used OR
- Patients should be referred into a specialist for consideration of de-prescribing if appropriate